Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 286, Issue 6 55-6, 2004, Pages

  L'Ecuyer, Thomas ^a,c   Allebban, Zuhair ^a   Thomas, Ronald ^a   Vander Heide, Richard ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Antioxidant; Apoptosis; Oncosis; Oxidative stress

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE ALPHA4; ISOPROTEIN; REACTIVE OXYGEN METABOLITE; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL COUNT; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ANALYSIS; FLUORESCENCE; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; NICK END LABELING; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; APOPTOSIS; CELL LINE; CELL MEMBRANE; DOXORUBICIN; FETUS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUTATHIONE TRANSFERASE; IN SITU NICK-END LABELING; MYOCARDIUM; OXIDATIVE STRESS; RATS; TRANSFECTION;

EID: 2542461224     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00778.2003     Document Type: Article

References (54)

1. Akao M, O'Rourke B, Teshima Y, Seharaseyon J, and Marban E. Mechanistically distinct steps in the mitochondrial death pathway triggered by oxidative stress in cardiac myocytes. Circ Res 92: 186-194, 2003.
2. Akao M, Ohler A, O'Rourke B, and Marban E. Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res 88: 1267-1275, 2001.
3. Al-Shabanah OA, Badary OA, Nagi MN, al-Gharably NM, al-Rikabi AC, and al-Bekairi AM. Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity. J Exper Clin Cancer Res 17: 193-198, 1998.
4. Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ, Roddam PL, Roman E, Cartwright RA, and Morgan GJ. Polymorphism in glutathione S-transferase PI is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 98: 11592-11597, 2001.
5. Ambrosone CB, Freudenheim JL, Thompson PA, Bowman E, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, and Shields PG. Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res 59: 602-606, 1999.
6. Aoki H, Kang PM, Hampe J, Yoshimura K, Noma T, Matsuzaki M, and Izumo S. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem 277: 10244-10250, 2002.
7. Bastholt L, Dalmark M, Gjedde SB, Pfeiffer P, Pedersen D, Sandberg E, Kjaer M, Mouridsen HT, Rose C, Nielsen OS, Jakobsen P, and Bentzen SM. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14: 1146-1155, 1996.
8. Busdar AU, Marcus C, Smith TL, and Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55: 2761-2765, 1985.
9. Chen YH, Lin SJ, Lin MW, Tsai HL, Kuo SS, Chen JW, Charng MJ, Wu TC, Chen LC, Ding YA, Pan WH, Jou YS, and Chau LY. Microsatellite polymorphism in promoter of heme oxygenase-I gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 111: 1-8, 2002.
10. Cusack BJ, Mushlin PS, Voulelis LD, Li X, Boucek RJ Jr, and Olson RD. Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol? Toxicol Appl Pharmacol 118: 177-185, 1993.
11. Cusack BJ, Young SP, Driskell J, and Olson RD. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32: 53-58, 1993.
12. De Atley SM, Aksenov MY, Aksenova MV, Harris B, Hadley R, Cole Harper P, Carney JM, and Butterfield DA. Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes. Cancer Lett 136: 41-46, 1999.
13. Dorr RT, Lagel K, and McLean S. Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro. Eur J Cancer 32A: S21-S25, 1996.
14. Fink FM, Genser N, Fink C, Falk M, Mair J, Maurer-Dengg K, Hammerer I, and Puschendorf B. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol 25: 185-189, 1995.
15. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, and Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766-1769, 1995.
16. Grenier MA and Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 25: 72-85, 1998.
17. Henrion-Caude A, Flamant C, Roussey M, Housset C, Flahault A, Fryer AA, Chadelat K, Strange RC, and Clement A. Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase PI polymorphism. Hepatology 36: 913-917, 2002.
18. Horenstein MS, Vander Heide RS, and L'Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab 71: 436-444, 2000.
19. Jeyaseelan R, Poizat C, and Wu H. Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein. ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J Biol Chem 272: 5828-5832, 1997.
20. Kang YJ, Chen Y, and Epstein PN. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem 271: 12610-12616, 1996.
21. Kim Y, Ma AG, Kitta K, Fitch SN, Ikeda T, Ihara Y, Simon AR, Evans T, and Suzuki YJ. Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol 63: 368-377, 2003.
22. Kimes BW and Brandt BL. Properties of a clonal muscle cell line from rat heart. Exp Cell Res 98: 367-381, 1976.
23. Krajinovic M, Labuda D, Richer C, Karimi S, and Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 93: 1496-1501, 1999.
24. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, and Voute PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 19: 191-196, 2001.
25. L'Ecuyer T, Horenstein MS, Thomas R, and Vander Heide R. Anthracycline-induced cardiac injury using a cardiac cell line: potential for gene therapy studies. Mol Genet Metab 74: 370-379, 2001.
26. L'Ecuyer TJ, Schulte D, and Lin JJC. Thin filament changes during in vivo rat heart development. Pediatr Res 30: 232-238, 1991.
27. Li T, Danelisen I, Bello-Klein A, and Singal PK. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res 46: 523-530, 2000.
28. Lorenzo E, Ruiz-Ruiz C, Quesada AJ, Hernandez G, Rodriguez A, Lopez-Rivas A, and Redondo JM. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 277: 10883-10892, 2002.
29. Meyer DJ, Crease DJ, and Ketterer B. Forward and reverse catalysis and product sequestration by human glutathione S-transferases in the reaction of GSH with dietary aralkyl isothiocyanates. Biochem J 306: 565-569, 1995.
30. Minotti G, Ronchi R, Salvatorelli E, Menna P, and Cairo G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 61: 8422-8428, 2001.
31. Muller I, Jenner A, Bruchelt G, Niethammer D, and Halliwell B. Effect of concentration on the cytotoxic mechanism of doxorubicin-apoptosis and oxidative DNA damage. Biochem Biophys Res Commun 230: 254-257, 1997.
32. Nakamura S, Kugiyama K, Sugiyama S, Miyamoto S, Koide S, Fukushima H, Honda O, Yoshimura M, and Ogawa H. Polymorphism in the 5′-flanking region of human glutamate-cysteine ligase modifier subunit gene is associated with myocardial infarction. Circulation 105: 2968-2973, 2002.
33. Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, and Koh E. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation 102: 572-578, 2000.
34. Negoro S, Oh H, Tone E, Kunisada K, Fujio Y, Walsh K, Kishimoto T, and Yamauchi-Takihara K. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 103: 555-561, 2001.
35. Nobori K, Ito H, Tamamori-Adachi M, Adachi S, Ono Y, Kawauchi J, Kitajima S, Marumo F, and Isobe M. ATF3 inhibits doxorubicin-induced apoptosis in cardiac myocytes: a novel cardioprotective role of ATF3. J Mol Cell Cardiol 34: 1387-1397, 2002.
36. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, Canetta R, Castellani R, Villa E, Gallagher CG, von Melchner H, Hayat M, Ribaud P, De Wasch G, Mattsson W, Heinz R, Waldner R, Kolaric K, Buehner R, Ten Bokkel-Huyninck W, Perevodchikova NI, Manziuk LA, Senn HJ, and Mayr AC. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Res 63: 827-834, 1979.
37. Sarvazyan N. Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. Am J Physiol Heart Circ Physiol 271: H2079-H2085, 1996.
38. Sawyer DB, Fukazawa R, Arstall MA, and Kelly RA. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 84: 257-265, 1999.
39. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, and Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105: 1551-1554, 2002.
40. Shioji K, Kishimoto C, Nakamura H, Masutani H, Yuan Z, Oka S, and Yodoi J. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 106: 1403-1409, 2002.
41. Siveski-Iliskovic N, Kaul N, and Singal PK. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 89: 2829-2835, 1994.
42. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, and Zeleniuch-Jacquotte A. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319: 745-752, 1988.
43. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, and Meyers M. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10: 117-127, 1992.
44. Trinei M, Giorgio M, Cicalese A, Barozzi S, Ventura A, Migliaccio E, Milia E, Padura IM, Raker VA, Maccarana M, Petronilli V, Minucci S, Bernardi P, Lanfrancone L, and Pelicci PG. A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis. Oncogene 21: 3872-3878, 2002.
45. Turner NA, Xia F, Azhar G, Zhang X, Liu L, and Wei JY. Oxidative stress induces DNA fragmentation and caspase activation via the c-Jun NH2-terminal kinase pathway in H9c2 cardiac muscle cells. J Mol Cell Cardiol 30: 1789-1801, 1998.
46. Uchida K, Shiraishi M, Naito Y, Torii Y, Nakamura Y, and Osawa T. Activation of stress signaling pathways by the end product of lipid peroxidation. 4-hydroxy-2-nonenal is a potential inducer of intracellular peroxide production. J Biol Chem 274: 2234-2242, 1999.
47. Von Harsdorf R, Li PF, and Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 99: 2934-2941, 1999.
48. Vora J, Khaw BA, Narula J, and Boroujerdi M. Protective effect of butylated hydroxyanisole on adriamycin-induced cardiotoxicity. J Pharm Pharmacol 48: 940-944, 1996.
49. Yamanaka S, Tatsumi T, Shiraishi J, Mano A, Keira N, Matoba S, Asayama J, Fushiki S, Fliss H, and Nakagawa M. Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Coll Cardiol 41: 870-878, 2003.
50. Yen HC, Oberley TD, Vichitbandha S, Ho YS, and St. Clair DK. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 98: 1253-1260, 1996.
51. Yoshizumi M, Kogame T, Suzaki Y, Fujita Y, Kyaw M, Kirima K, Ishizawa K, Tsuchiya K, Kagami S, and Tamaki T. Ebselen attenuates oxidative stress-induced apoptosis via the inhibition of the c-Jun N-terminal kinase and activator protein-1 signalling pathway in PC12 cells. Br J Pharmacol 136: 1023-1032, 2002.
52. Zhou X, Zhai X, and Ashraf M. Direct evidence that initial oxidative stress triggered by preconditioning contributes to second window of protection by endogenous antioxidant enzyme in myocytes. Circulation 93: 1177-1184, 1996.
53. Zhu W, Zou Y, Aikawa R, Harada K, Kudoh S, Uozumi H, Hayashi D, Gu Y, Yamazaki T, Nagai R, Yazaki Y, and Komuro I. MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation 100: 2100-2107, 1999.
54. Zimniak L, Awasthi S, Srivastava SK, and Zimniak P. Increased resistance to oxidative stress in transfected cultured cells overexpressing glutathione S-transferase mGSTA4-4. Toxicol Appl Pharmacol 143: 221-229, 1997.